[HTML][HTML] Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS® trials

…, V Cottin, RM Du Bois, M Selman, T Kimura, Z Bailes… - Respiratory …, 2016 - Elsevier
Background and purpose The Phase II TOMORROW trial and two Phase III INPULSIS ® trials
investigated the efficacy and safety of nintedanib versus placebo in patients with idiopathic …

Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind …

LA Lee, Z Bailes, N Barnes, LP Boulet… - The Lancet …, 2021 - thelancet.com
Background Despite inhaled corticosteroid plus long-acting β 2 -agonist (ICS/LABA) therapy,
30–50% of patients with moderate or severe asthma remain inadequately controlled. We …

Subgroup analysis of Asian patients in the INPULSIS® trials of nintedanib in idiopathic pulmonary fibrosis

…, A Azuma, Y Inoue, H Li, T Fujimoto, Z Bailes… - …, 2016 - Wiley Online Library
Background and objective In the two‐replicate randomized Phase III INPULSIS ® trials in
patients with idiopathic pulmonary fibrosis ( IPF ), nintedanib 150 mg bd significantly reduced …

Effect of anti-acid medication on reduction in FVC decline with nintedanib

G Raghu, B Crestani, Z Bailes, R Schlenker-Herceg… - 2015 - Eur Respiratory Soc
Background: It has been suggested that anti-acid medication may impact the progression of
idiopathic pulmonary fibrosis (IPF). The two replicate, 52-week, Phase III INPULSIS о trials …

[HTML][HTML] Clinic vs home spirometry for monitoring lung function in patients with asthma

…, NA Hanania, R Chaudhuri, H Sagara, Z Bailes… - Chest, 2023 - Elsevier
Background Studies examining agreement between home and clinic spirometry in patients
with asthma are limited, with conflicting results. Understanding the strengths and limitations …

[HTML][HTML] Efficacy and safety of linagliptin co-administered with low-dose metformin once daily versus high-dose metformin twice daily in treatment-naïve patients with …

L Ji, B Zinman, S Patel, J Ji, Z Bailes, S Thiemann… - Advances in …, 2015 - Springer
Introduction The aim of this study was to investigate the efficacy and safety of linagliptin +
low-dose (LD) metformin once daily versus high-dose (HD) metformin twice daily in treatment-…

[HTML][HTML] A phase IIb, randomised, parallel-group study: the efficacy, safety and tolerability of once-daily umeclidinium in patients with asthma receiving inhaled …

E Kerwin, S Pascoe, Z Bailes, R Nathan… - Respiratory …, 2020 - Springer
Background Patients with asthma uncontrolled on inhaled corticosteroids may benefit from
umeclidinium (UMEC), a long-acting muscarinic antagonist. Methods This Phase IIb, double-…

Oral glucose lowering with linagliptin and metformin compared with linagliptin alone as initial treatment in Asian patients with newly diagnosed type 2 diabetes and …

…, D Lewis‐D'Agostino, Z Bailes… - Journal of Diabetes …, 2018 - Wiley Online Library
Aims/Introduction Type 2 diabetes mellitus is an epidemic in Asia, yet clinical trials of
glucose‐lowering therapies often enroll predominantly Western populations. We explored the initial …

[HTML][HTML] Measuring respiratory symptoms in moderate/severe asthma: evaluation of a respiratory symptom tool, the E-RS®: COPD in asthma populations

…, H Karn, R Hsieh, TA Howell, Z Bailes… - Journal of Patient …, 2021 - Springer
Background Symptom constructs included in the Evaluating Respiratory Symptoms in
Chronic Obstructive Pulmonary Disease (E-RS®: COPD) tool may be relevant to patients with …

Linagliptin plus metformin in patients with newly diagnosed type 2 diabetes and marked hyperglycemia

…, B Gallwitz, D Lewis-D'Agostino, Z Bailes… - Postgraduate …, 2016 - Taylor & Francis
Objectives: Few studies of oral glucose-lowering drugs exist in newly diagnosed type 2
diabetes (T2D) patients with marked hyperglycemia, and insulin is often proposed as initial …